The German reimbursement authority renewed payment coding for Medovex’s DenerveX™ technology for the treatment of the facet joint syndrome for 2017.
While DenerveX is not yet CE-Marked or FDA-cleared, leadership expects that the renewal will be a significant driver for European launch preparation. The company has already confirmed first distributor partnerships.
The German reimbursement authority renewed payment coding for Medovex's DenerveX™ technology for the treatment of the facet joint syndrome for 2017.
While DenerveX is not yet CE-Marked or FDA-cleared, leadership expects that the renewal will be a significant driver for European launch preparation. The...
The German reimbursement authority renewed payment coding for Medovex’s DenerveX™ technology for the treatment of the facet joint syndrome for 2017.
While DenerveX is not yet CE-Marked or FDA-cleared, leadership expects that the renewal will be a significant driver for European launch preparation. The company has already confirmed first distributor partnerships.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
